ES2102009T3 - Tratamiento para el asma. - Google Patents

Tratamiento para el asma.

Info

Publication number
ES2102009T3
ES2102009T3 ES93902914T ES93902914T ES2102009T3 ES 2102009 T3 ES2102009 T3 ES 2102009T3 ES 93902914 T ES93902914 T ES 93902914T ES 93902914 T ES93902914 T ES 93902914T ES 2102009 T3 ES2102009 T3 ES 2102009T3
Authority
ES
Spain
Prior art keywords
asthma
treatment
eosinophils
polypeptide
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93902914T
Other languages
English (en)
Other versions
ES2102009T5 (es
Inventor
Roy R Lobb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25234272&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2102009(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of ES2102009T3 publication Critical patent/ES2102009T3/es
Publication of ES2102009T5 publication Critical patent/ES2102009T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE PRESENTA UN METODO PARA EL TRATAMIENTO DEL ASMA. EL METODO COMPRENDE LA ADMINISTRACION DE UN ANTICUERPO, POLIPEPTIDO U OTRA MOLECULA QUE RECONOCE VLA-4, UNA PROTEINA EXPRESADA SOBRE LA SUPERFICIE DE CIERTOS LEUCOCITOS TALES COMO EOSINOFILOS.
ES93902914T 1992-01-13 1993-01-12 Tratamiento para el asma. Expired - Lifetime ES2102009T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82176892A 1992-01-13 1992-01-13

Publications (2)

Publication Number Publication Date
ES2102009T3 true ES2102009T3 (es) 1997-07-16
ES2102009T5 ES2102009T5 (es) 2004-12-16

Family

ID=25234272

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93902914T Expired - Lifetime ES2102009T5 (es) 1992-01-13 1993-01-12 Tratamiento para el asma.

Country Status (10)

Country Link
EP (1) EP0626861B2 (es)
JP (4) JPH07506091A (es)
AT (1) ATE150319T1 (es)
CA (1) CA2127462C (es)
DE (1) DE69309044T3 (es)
DK (1) DK0626861T4 (es)
ES (1) ES2102009T5 (es)
GR (1) GR3023203T3 (es)
HK (1) HK1007682A1 (es)
WO (1) WO1993013798A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
EP0670735B1 (en) 1992-11-13 1997-04-02 Board Of Regents Of The University Of Washington Peripheralization of hematopoietic stem cells
NZ261259A (en) * 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
AU727187B2 (en) * 1993-02-09 2000-12-07 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
JP3593343B2 (ja) * 1993-02-09 2004-11-24 バイオジェン インコーポレイテッド インシュリン依存型糖尿病の治療
ZA947006B (en) * 1993-09-15 1995-05-02 Univ Emory Method of inhibiting binding of reticulocytes to endothelium by interfering with vla-4/vcam-1 interactions
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647382A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
AU757873B2 (en) 1998-09-14 2003-03-06 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
PL198975B1 (pl) 1999-04-22 2008-08-29 Biogen Idec Inc Zastosowanie kompozycji zawierającej homolog przeciwciała, który jest antagonistą interakcji między integryną niosącą podjednostkę alfa 4 a jej ligandem
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
HK1043320A1 (zh) 1999-06-01 2002-09-13 Biogen, Inc. Vla-1的一种阻塞性单系抗体，以及其治疗炎性失调的功用
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
UA83791C2 (ru) 2001-04-13 2008-08-26 Байоджен Айдек Ма Инк. Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
EP1477482B1 (en) 2002-02-20 2010-04-14 Ajinomoto Co., Inc. Novel phenylalanine derivative
EP1700850B1 (en) 2003-12-22 2015-07-15 Ajinomoto Co., Inc. Phenylalanine derivative
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
BRPI0712607A8 (pt) 2006-05-25 2019-06-04 Biogen Idec Inc métodos de tratamento de acidente vascular cerebral
EP2510941A3 (en) 2007-02-20 2013-01-23 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
BRPI0911652A2 (pt) 2008-04-11 2015-08-04 Merrimack Pharmaceuticals Inc Ligantes de albumina sérica humana e seus conjugados
EA201291065A1 (ru) 2010-04-16 2013-03-29 Байоджен Айдек Ма Инк. Антитела против vla-4
ES2732243T3 (es) 2012-02-16 2019-11-21 Santarus Inc Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
JP7457661B2 (ja) 2018-06-04 2024-03-28 バイオジェン・エムエイ・インコーポレイテッド 低減したエフェクター機能を有する抗ｖｌａ－４抗体
EP4093508A1 (en) 2020-01-24 2022-11-30 Pfizer Inc. Anti-e-selectin antibodies, compositions and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) † 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) † 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL95501A (en) 1989-09-01 1997-04-15 Hutchinson Fred Cancer Res Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
DK162890D0 (da) 1990-07-06 1990-07-06 Novo Nordisk As Polypeptid

Also Published As

Publication number Publication date
JP2003176239A (ja) 2003-06-24
JP2010285444A (ja) 2010-12-24
DK0626861T4 (da) 2004-08-16
JP2006316070A (ja) 2006-11-24
EP0626861B2 (en) 2004-04-28
ES2102009T5 (es) 2004-12-16
DE69309044T3 (de) 2004-12-23
AU665232B2 (en) 1995-12-21
CA2127462C (en) 1999-03-23
AU3431793A (en) 1993-08-03
JP4590152B2 (ja) 2010-12-01
JPH07506091A (ja) 1995-07-06
GR3023203T3 (en) 1997-07-30
HK1007682A1 (en) 1999-04-23
EP0626861A1 (en) 1994-12-07
ATE150319T1 (de) 1997-04-15
DE69309044T2 (de) 1997-09-25
DK0626861T3 (da) 1997-09-22
DE69309044D1 (de) 1997-04-24
CA2127462A1 (en) 1993-07-22
WO1993013798A1 (en) 1993-07-22
EP0626861B1 (en) 1997-03-19

Similar Documents

Publication Publication Date Title
ES2102009T5 (es) Tratamiento para el asma.
ES2114183T3 (es) Anticuerpo para el tratamiento de la diabetes dependiente de la insulina.
CY1114164T1 (el) Μεθοδος ελεγχου της δραστικοτητας ανοσολογικα λειτουργικου μοριου
ITTO920695A0 (it) Sistema di riconoscimento, particolarmente per il riconoscimento di persone
ITRM940209A0 (it) Procedimento in due stadi per la produzione di policarbonato termopla-stico.
DK0538300T3 (da) O-Glycosyleret IFN-alfa
DE69227041D1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
NO971875L (no) Cathepsin 02 protease
FI943389L (fi) Bacillus-lajista saatu ksylanaasi, tällaisen ksylanaasin ja muiden proteiinien ekspressiovektori, niiden isäntäorganismit ja käyttö
MX9101526A (es) Nuevo metodo para tratar la depresion
HU9501288D0 (en) Recombinant method and host for manufacture of xylitol
DE3770915D1 (de) Menschliches apolipoprotein a1 sowie dessen variante, exprimiert in escherichia coli.
DK0646176T3 (da) Levering og ekspression af et hybridoverfladeprotein på overfladen af grampositive bakterier
DK38889D0 (da) Onkogen-indkodet polypeptid med vaekstfaktoraktivitet
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
PT90739A (pt) Processo para a preparacao de uma proteina dotada de actividade de inibicao de trombina
EP1251176A3 (en) Expression systems utilizing autolyzing fusion proteins and a reducing polypeptide
ATE93527T1 (de) Peptide und deren benutzung.
CA2088478A1 (en) Cloning and expression of a rhoptry associated protein of p. falciparum
SE8403929L (sv) Rekombinant-dna-molekyl, transformerade mikroorganismer och forfarande for framstellning av penicillin v-amidas
BR9205877A (pt) Processo e composiçao para o tratamento de infecçoes por herpes.
ITTO921024A1 (it) Procedimento per la fabbricazione di nastri pieghettatori e increspatori fissabili mediante contatto.
IT1226147B (it) Processo per la preparazione di perfluoro (2 bromoetilviniletere).
WO1998001550A3 (en) Vaccine against gastro-intestinal nematodes
ITBZ930044A0 (it) Procedimento per la ricerca di anticorpi anti-endomisio umani.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 626861

Country of ref document: ES